Holen Sie sich die Stockscreener-App
4.6662
0.71%
-0.0338
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Will Recursion Pharmaceuticals Inc. stock benefit from infrastructure spendingStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing - MarketScreener
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Aug Setups: How Recursion Pharmaceuticals Inc. stock performs after earningsJuly 2025 Opening Moves & Safe Entry Momentum Tips - ulpravda.ru
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Stock Surges: What’s Happening? - timothysykes.com
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC - simplywall.st
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Insider Monkey
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Yahoo Finance
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares - MarketBeat
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares By Investing.com - Investing.com UK
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares - Investing.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares - MarketBeat
Recursion Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
RXRX Stock Plummet: Here’s What’s Happening - timothysykes.com
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP - Insider Monkey
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
10 AI Stocks Under $20 to Buy Now - Insider Monkey
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform - Finviz
Cathie Wood is doubling down on Recursion Pharmaceuticals stock. Should you buy RXRX here? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
Growth or Bubble? Decoding Recursion Pharmaceuticals’ Stock Surge - timothysykes.com
3 Small AI Plays to Buy for 2026 - Sahm
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):